| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 1.2MM | - |
| Gross Profit | 737K | - |
| Cost Of Revenue | 440K | - |
| Operating Income | -702K | +5% |
| Operating Expenses | 1.4MM | +41% |
| Net Income | -813K | +12% |
| R&D | 62K | +88% |
| G&A | 1.1MM | +44% |
| Marketing | 233K | +23% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
1x1 Meetings on Thursday, May 2, 2024 ELMSFORD, NY / ACCESSWIRE / April 24, 2024 / NanoVibronix, Inc. (Nasdaq:NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShieldâ, PainShieldâ and WoundShieldâ Surface Acoustic ...
ELMSFORD, N.Y., April 09, 2024--NanoVibronix, Inc., (NASDAQ: NAOV)("NanoVibronix"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the fourth quarter and full year 2023 and recent business developments.
ELMSFORD, N.Y., March 28, 2024--NanoVibronix, Inc. (Nasdaq: NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an agreement with Veranex, Inc. ("Veranex") to assist with the development of the company’s next generation UroShield and PainShield products.
ELMSFORD, N.Y., December 06, 2023--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its UroShield is featured in Issue 103 of Your Bladder Health Magazine in an article titled ‘UroShield Prevention is better than cure.’ The article highlights the effectiveness of using UroShield in the prevention of catheter associated urinary tract infe
ELMSFORD, N.Y., December 04, 2023--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a non-binding letter of intent (the "LOI") with APOGEPHA Arzneimittel GmbH ("APOGEPHA") in which both parties will analyze the potential for APOGEPHA to distribute NanoVibronix’s premiere UroShield product in Germany and other European
ELMSFORD, N.Y., November 28, 2023--NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial ("RCT") study of UroShield.
ELMSFORD, N.Y., November 21, 2023--NanoVibronix, Inc., (NASDAQ: NAOV) (the "Company"), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that on November 20, 2023, the Company received official notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the minimum stockholders’ eq
ELMSFORD, N.Y., November 14, 2023--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the third quarter 2023 and recent business developments.
ELMSFORD, N.Y., November 07, 2023--NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that effective November 1, its UroShield actuators are eligible for reimbursement on NHS Prescription Services’ Drug Tariff.
ELMSFORD, N.Y., September 27, 2023--NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its application for UroShield actuators to be available on NHS Prescription Services’ Drug Tariff has been approved.